NSE NATCOPHARM · BSE 524816 · Biotechnology & Drugs · NIFTY 500
Natco Pharma Share Price
Natco Pharma Overview
Where the price stands, how it has moved and how it sits against its averages.
Natco Pharma shares last traded at ₹842.00 on the NSE, up 0.79% on the day. That is 31.3% below the 52-week high of ₹1,226.10 and 6.7% above the 52-week low of ₹789.30. The stock trades at 13.22× earnings. Its market value is ₹15,126 Cr.
Price returns
Shading grows with the size of the move. We ask our data provider for a newer price every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next check from Mon 26 Oct, 9:15 AM. Its quotes are not real-time — the time at the top shows how current the price is.
Moving averages — price is above 3 of 6
- 100-day average₹947.40 ▼ price 11.1% below
- 300-day average₹942.50 ▼ price 10.7% below
- 50-day average₹886.72 ▼ price 5.0% below
- Today's price₹842.00
- 20-day average₹833.09 ▲ price 1.1% above
- 10-day average₹818.15 ▲ price 2.9% above
- 5-day average₹815.26 ▲ price 3.3% above
Each average is the mean closing price over that many trading days; averages above the current price sit higher on the ladder.
Natco Pharma Financial Results
Revenue and net profit in ₹ crore, with the full statements underneath.
Year by year
| Fiscal year | Revenue | Growth | Net profit | Net margin | EPS | Dividend |
|---|---|---|---|---|---|---|
| FY 2026 | ₹4,078 Cr | ▼ −7.9% | ₹1,419 Cr | 34.8% | ₹79.20 | ₹5.00 |
| FY 2025 | ₹4,430 Cr | ▲ +10.8% | ₹1,885 Cr | 42.6% | ₹105.27 | ₹6.00 |
| FY 2024 | ₹3,999 Cr | ▲ +47.7% | ₹1,388 Cr | 34.7% | ₹77.34 | ₹9.50 |
| FY 2023 | ₹2,707 Cr | ▲ +39.2% | ₹715 Cr | 26.4% | ₹39.18 | ₹5.50 |
| FY 2022 | ₹1,945 Cr | ▼ −5.2% | ₹170 Cr | 8.7% | ₹9.32 | ₹4.50 |
| FY 2021 | ₹2,052 Cr | ▲ +7.2% | ₹441 Cr | 21.5% | ₹24.16 | ₹5.25 |
| FY 2020 | ₹1,915 Cr | — | ₹461 Cr | 24.1% | ₹25.26 | ₹6.75 |
Quarter by quarter
| Quarter | Revenue | vs prev. qtr | Net profit | Net margin | EPS |
|---|---|---|---|---|---|
| Q1 FY27 | ₹735 Cr | ▼ −0.5% | ₹207 Cr | 28.1% | ₹11.53 |
| Q4 FY26 | ₹739 Cr | ▲ +14.2% | ₹268 Cr | 36.2% | ₹14.96 |
| Q3 FY26 | ₹647 Cr | ▼ −52.5% | ₹152 Cr | 23.4% | ₹8.46 |
| Q2 FY26 | ₹1,363 Cr | ▲ +2.6% | ₹518 Cr | 38.0% | ₹28.94 |
| Q1 FY26 | ₹1,329 Cr | ▲ +8.8% | ₹481 Cr | 36.2% | ₹26.84 |
| Q4 FY25 | ₹1,221 Cr | ▲ +157.2% | ₹407 Cr | 33.3% | ₹22.70 |
| Q3 FY25 | ₹475 Cr | ▼ −65.4% | ₹133 Cr | 28.0% | ₹7.43 |
| Q2 FY25 | ₹1,371 Cr | — | ₹677 Cr | 49.4% | ₹37.81 |
Balance sheet — FY26
- Total assets₹11,074 Cr
- Total liabilities₹1,853 Cr
- Shareholders' equity₹9,221 Cr
- Total debt₹714 Cr
- Cash & investments₹2,125 Cr
Cash flow — FY26
Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.
Full financial statements, FY20–FY26
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total revenue | 1,915.00 | 2,052.10 | 1,944.80 | 2,707.10 | 3,998.80 | 4,429.50 | 4,078.30 |
| Cost of revenue | 498.90 | 609.90 | 676.70 | 749.10 | 865.60 | 848.30 | 895.40 |
| Gross profit | 1,416.10 | 1,442.20 | 1,268.10 | 1,958.00 | 3,133.20 | 3,581.20 | 3,182.90 |
| Operating expenses | 1,432.20 | 1,562.80 | 1,823.90 | 1,930.10 | 2,431.40 | 2,468.70 | 2,823.30 |
| Operating income | 482.80 | 489.30 | 120.90 | 777.00 | 1,567.40 | 1,960.80 | 1,255.00 |
| Depreciation | 99.80 | 116.90 | 142.60 | 163.80 | 186.80 | 185.20 | 206.10 |
| Profit before tax | 568.70 | 579.60 | 202.20 | 861.90 | 1,673.50 | 2,291.40 | 1,490.80 |
| Tax | 110.60 | 137.20 | 32.20 | 146.60 | 285.20 | 408.00 | 118.90 |
| Net profit | 460.80 | 440.90 | 170.00 | 715.30 | 1,388.30 | 1,885.40 | 1,418.50 |
| EPS (₹) | 25.26 | 24.16 | 9.32 | 39.18 | 77.34 | 105.27 | 79.20 |
| Dividend per share (₹) | 6.75 | 5.25 | 4.50 | 5.50 | 9.50 | 6.00 | 5.00 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Total assets | 4,587.80 | 4,791.90 | 5,109.10 | 5,657.40 | 6,906.30 | 8,630.80 | 11,073.70 |
| Current assets | 2,325.60 | 2,337.30 | 2,497.20 | 3,000.30 | 4,023.50 | 5,270.00 | 5,052.30 |
| Cash & short-term investments | 91.30 | 424.10 | 406.10 | 793.10 | 1,391.20 | 2,489.90 | 2,124.50 |
| Inventory | 698.70 | 910.40 | 862.00 | 808.90 | 791.70 | 849.40 | 989.80 |
| Property, plant & equipment | 2,093.60 | 2,237.20 | 2,308.40 | 2,303.40 | 2,435.00 | 2,657.30 | 2,839.10 |
| Total liabilities | 814.30 | 670.30 | 845.50 | 783.60 | 1,053.20 | 1,023.80 | 1,852.60 |
| Current liabilities | 685.30 | 525.60 | 710.40 | 683.10 | 972.80 | 943.50 | 1,680.90 |
| Total debt | 315.90 | 267.60 | 415.50 | 166.70 | 371.20 | 279.40 | 713.90 |
| Total equity | 3,773.50 | 4,121.60 | 4,263.60 | 4,873.80 | 5,853.10 | 7,607.00 | 9,221.10 |
| ₹ crore | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| From operations | 417.30 | 298.80 | 46.50 | 849.10 | 1,211.60 | 1,696.80 | 1,768.30 |
| From investing | −167.00 | −103.30 | −5.30 | −477.10 | −1,032.70 | −1,414.50 | −2,081.70 |
| From financing | −250.80 | −185.70 | 34.80 | −363.00 | −246.90 | −210.70 | 297.50 |
| Capital expenditure | −358.60 | −254.60 | −232.80 | −205.60 | −358.70 | −511.60 | −391.10 |
| Dividends paid | −153.60 | −113.90 | −82.20 | −100.40 | −170.80 | −107.80 | −90.20 |
| Net change in cash | −8.50 | 6.00 | 85.30 | 20.80 | −61.50 | 49.60 | 78.90 |
Natco Pharma vs Peers
Side by side with other biotechnology & drugs companies. The small bars compare each column.
| Company | Price | Change | Market cap | P/E | P/B | ROE (5 yr) | Net margin | Div. yield |
|---|---|---|---|---|---|---|---|---|
| Natco Pharma This stock | ₹842.00 | ▲ +0.79% | ₹15,126 Cr | 13.22 | 1.64 | — | — | 0.59% |
| Sun Pharmaceutical Industries | ₹1,853.00 | ▼ −0.64% | ₹4,44,586 Cr | 38.40 | 5.55 | 14.22% | 19.12% | 0.83% |
| Divi's Laboratories | ₹9,613.00 | ▲ +0.17% | ₹2,55,195 Cr | 73.32 | 11.48 | 16.87% | 24.32% | 0.41% |
| Torrent Pharmaceuticals | ₹4,935.00 | ▼ −0.90% | ₹1,87,705 Cr | 72.73 | 19.22 | 23.00% | 15.29% | 0.80% |
| Cipla | ₹1,404.00 | ▲ +1.74% | ₹1,13,423 Cr | 27.57 | 3.33 | 14.47% | 13.74% | 0.92% |
| Zydus Lifesciences | ₹1,180.00 | ▲ +0.90% | ₹1,17,705 Cr | 21.19 | 4.24 | 17.90% | 18.51% | 0.09% |
Peer prices and ratios as last reported by the data provider. Company names link to their own pages.
Natco Pharma Key Metrics
Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.
Valuation The price against earnings, book value and sales
Returns & efficiency How well does it use its money?
Growth Is the business getting bigger?
Financial strength Can it pay its bills and debts?
Per share What each share stands for
The share price is 1.64× the book value behind each share.
Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.
Dividends & Corporate Events
Payouts to shareholders, splits and bonus issues, and company meetings — newest first.
- Dividend yield0.59%
- Payout ratio6.31%
- Latest dividend₹1.50 per share · 20 Aug 2026
Corporate calendar
- MeetingAnnual General Meeting
- BoardRights issue of Equity Shares
- BoardFund Raising
- Dividend₹1.50 per share · 75% · Interim dividend
- BoardQuarterly Results & Interim Dividend
- BoardAudited Results
- MeetingPostal Ballot
- BoardScheme of Arrangement
Show 14 older events
- Dividend₹1.50 per share · 75% · Interim dividend
- BoardQuarterly Results & Interim Dividend
- Dividend₹1.50 per share · 75% · Interim dividend
- BoardQuarterly Results & Interim Dividend
- MeetingAnnual General Meeting
- Dividend₹2.00 per share · 100% · Interim dividend
- BoardQuarterly Results & Interim Dividend
- Dividend₹1.50 per share · 75% · Interim dividend
- Dividend₹1.50 per share · 75% · Interim dividend
- Dividend₹3.00 per share · 150% · Interim dividend
- MeetingPostal Ballot
- Dividend₹1.25 per share · 63% · Interim dividend
- MeetingAnnual General Meeting
- MeetingPostal Ballot
About Natco Pharma
Biotechnology & Drugs
Natco Pharma Limited is an India-based vertically integrated pharmaceutical company with a focus on research and development. It develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. Its segments include Pharmaceuticals and Agro chemicals. The Pharmaceuticals segment is engaged in the manufacturing and selling of bulk drugs, finished dosage formulations. The Agro Chemicals segment focuses on the manufacturing and selling of agro chemicals. It is also engaged in developing, manufacturing and marketing finished dosage formulations (FDF), active pharmaceutical ingredients (APIs) and intermediates. Its product portfolio consists of two categories of agrochemicals - pesticides and bioproducts. The key focus area is to fill the gaps in the portfolio through crop phenology analysis. It has manufacturing facilities in India which cater to both domestic and international markets.
Key people
- Venkaiah Chowdary NannapaneniChairman of the Board, Managing Director, Executive Director
- Rajeev NannapaneniChief Executive Officer, Vice Chairman of the Board, Executive Director
- Amit ParekhChief Financial Officer
- Linga Rao DonthineniPresident - Technical Affairs, Executive Director
- Potluri Sivaramakrishna PrasadExecutive Vice President - Corporate Engineering Services, Executive Director
- Rajesh ChebiyamExecutive Vice President - Crop Health Sciences
Company facts
- NSE symbolNATCOPHARM
- BSE code524816
- ISININE987B01026
- IndustryBiotechnology & Drugs
- IndexNIFTY 500
- Market cap₹15,126 Cr
- Revenue (FY26)₹4,078 Cr
- Net profit (FY26)₹1,419 Cr
In the News
Recent headlines about Natco Pharma — they open on Mint in a new tab.
- Domestic pharma market sustains growth momentum, but margins remain key
Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance.
16 Sep 2026 · 3 min read · Mint ↗ - Natco Pharma looks beyond generics for its next growth shot
Chief executive and vice chairman Rajeev Nannapaneni lays bare the changing face of global pharma, explaining why Indian generics firms are scouting for new opportunities.
1 Sep 2026 · 4 min read · Mint ↗ - After the lottery win: why Dr Reddy’s may be doing much more in its laboratories
The pharmaceutical company rode one copycat drug to record profits. Now, co-chairman G.V. Prasad has to prove the company can grow without it. Biosimilars and innovation may hold the answer.
24 Aug 2026 · 11 min read · Mint ↗ - Stocks to watch: Reliance Industries, Cochin Shipyard, NMDC among shares in focus today; check list here
Stock market today: Gift Nifty was trading near the 24,393.5 mark, down over 56 points from the previous close of Nifty futures.
17 Aug 2026 · 2 min read · Mint ↗ - Top Gainers & Losers on 13 August: Apar Industries, Hindalco, Ather Energy, Force Motors, CUB among top losers
Indian stocks slid further, driven down by weak financial participation and high crude oil prices. The Nifty decreased by 0.34% and Sensex by 0.13%, with key sectors like metals and cement seeing significant losses amid ongoing geopolitical tensions.
13 Aug 2026 · 2 min read · Mint ↗ - Natco challenges Novartis’s second patent for cancer drug ribociclib in Delhi High Court
Natco claims the new patent unlawfully extends Novartis’s market monopoly over the breast cancer medicine past 2027; Delhi High Court issues notices to all parties.
5 Aug 2026 · 4 min read · Mint ↗
Stock data comes from the exchange feed via our data provider. It is not real-time and can be delayed, so check the price with your broker before you trade. This page is for information and education only. It is not investment advice, research or a recommendation to buy, sell or hold any security. Investments in the securities market are subject to market risks; read all related documents carefully before investing. See all stocks →